10 Overlooked Healthcare Stocks to Invest in

4. Organon & Co. (NYSE:OGN)

Number of Hedge Fund Holders: 35 

Organon & Co. (NYSE:OGN) is a pharmaceutical company focused on women’s health and biosimilars. In Q2 2025, the company reported $1.594 billion in revenue and an adjusted EPS of $1.00, slightly exceeding market expectations. Despite a modest year-over-year revenue decline, the company raised its full-year 2025 revenue guidance to $6.275–$6.375 billion, reflecting confidence in recovery driven by new product launches and biosimilar expansion.

Organon & Co. (NYSE:OGN) is actively managing its debt profile, aiming to reduce net leverage below 4.0x by the end of 2025 and further to 3.5x by 2026, while implementing cost-saving measures to increase operational flexibility. For investors searching for overlooked stocks with turnaround potential, OGN’s progress in strengthening its balance sheet and advancing its portfolio makes it a compelling case. Key portfolio developments include VTAMA (tapinarof) cream, which is advancing in market access, and biosimilars expected to offset losses from legacy drugs like Atozet in Europe.

Organon & Co. (NYSE:OGN)’s strategy emphasizes innovation in women’s health and biosimilars to counter competitive and regulatory pressures. CEO Kevin Ali’s recent stock purchase highlights confidence in the business’s trajectory.